Edison Investment Research - Ekso Bionics Holdings (EKSO) Update: Accelerating unit shipments

Report

Edison Investment Research

Update: Accelerating unit shipments

Ekso Bionics is a development-stage company that produces human robotic exoskeletons, or wearable robots. Recent data confirm that the companyâ€™s Ekso GT system for lower-body paralysis and weakness rehabilitation is experiencing accelerating sales to hospitals, and Ekso Bionics has recently offered to redeem outstanding warrants to raise money and avoid dilution.

06/11/2014 6 EN

Underlying

Ekso Bionics Holdings

See profile

United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Ekso Bionics Holdings (EKSO). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

March 1, 2016 March 1, 2016 1 EN

Edison Investment Research

Update: Unappreciated upside potential from industrials

The recent share price volatility is one of the risks of investing in early stage companies like Ekso but it should not detract from the fact that Ekso is one of the leading players in the exciting, emerging field of assistive exoskeletons. It is the only company that is targeting military, industrial and healthcare applications and the third contract secured with SOCOM on the TALOS project should illustrate the quality of its technology and engineers. Although risk will remain, there is substantial upside potential for those willing to ride out the volatility and hold in for the long term.

June 11, 2015 June 11, 2015 5 EN

Edison Investment Research

Update: Growing interest in non-medical applications

Ekso showed continued strength in Q4 both in medical applications and in Engineering services. 18 units were placed in the period, bringing the total number of units in use to 110 with 17m steps taken. Encouragingly, management also reports strong interest in Eksoâ€™s non-powered exoskeleton for industrial applications. We have lowered our forecast ASP from $120k to $110k to be consistent with the implied ASP over FY14, which has reduced our FY15 and FY16 revenue forecasts by 10% and 12% respectively, but we remain optimistic about the outlook. The opportunity in non-medical applications in pa...

April 21, 2015 April 21, 2015 6 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Accelerating unit shipments

Update: Termination of coverage

Update: Unappreciated upside potential from industrials

Update: Growing interest in non-medical applications

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe